Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination

Mario Giuliano(Regione Campania), Massimo Cristofanilli(Cornell University), Summer Jackson(The University of Texas MD Anderson Cancer Center), Simone Anfossi(The University of Texas MD Anderson Cancer Center), James M. Reuben(The University of Texas MD Anderson Cancer Center), Michal Mego(Comenius University Bratislava), Evan N. Cohen(The University of Texas MD Anderson Cancer Center), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Sabino De Placido, Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Hui Gao(Tiangong University), Ricardo H. Álvarez(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Beverly C. Handy(The University of Texas MD Anderson Cancer Center), Antonio Giordano(University of Siena)
Breast Cancer Research
September 15, 2014
10.1186/s13058-014-0440-8
Cited by 122

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k